representations regarding high prices and wrong exclusion of these medicines from price control; and

(h) if so, what are the details thereof and what action has been taken thereon?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL) : (a) Yes, Sin

(b) to (f) The required details to the extent available will be collected and laid on the Table of the Rajya Sabha.

(g) and (h) After considering the various representations about inclusion/exclusion of drugs under price control the Kelkar Committee in its supplementary report did not recommend inclusion of the bulk drugs contained in these formulations under price control.

Overcharged amounts on Proxyvon Range of formulations

2426. SHRI MOHD. KHALEELUR REHMAN: Will the Minister of INDUSTRY be pleased to refer to the answer given to Unstarred Question 4 given in the Rajya Sabha on the 24th April, 1989 and state :

(a) whether the details for recovering the overcharged amounts in respect of Proxyvon range formulations have since been received;

(b) if so, what are the details thereof and if not, what are the reasons therefor ; and

(c) what action is being taken in the matter?

THE MINISTER OF STATE IN THE MINISTRYOF PARLIAMENTARY AFFARS AND THE MINISTER OF STATE IN THF DEPARTMENT OF CHEMICALS AND PETROCHEMICALS INTHE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) to (c) The required details are still awaited from the company. The matter is being pursued,

Overcharging on drug formulations

2427. SHRI B. SATYANARAYAN REDDY: Will the Minister of INDUSTRY be pleased to state:

(a) whether it fs a fact that instances of overcharging the prices of Dextropropoxyphene and its formulations, Metronidazole and its formulations, Analgin and its formulations, Doxycycline and its formulations, Gentamycin and its formulations, Dexamethasone formulations, Flucinolone formulations came to the notice of his Ministry;

(b) if so, when did each instance came to the notice;

(c) what action was taken against each company under Essential Com modities Act;

(d) whether his Ministry worked out the overcharging in these cases;

(e) if so, what are the name of drug producer, rate of recovery and quantity taken into account; and

(f) by when the amount from other companies would be recovered ?

THE MINISTER OF STATE IN j THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (d) to (c) The liability of some of the formulations arising irnder paragraph 7 (2) of **DPCO,** 1979 came to the notice of the Government and letters fo about 230 formula-

tors were issued between 1983 and 1986 for collecting necessary data in order to work out the amount recoverable under the said provisions of DPCO, 1979.

(d)and(e) The details of tentative amounts worked out in respect of drugs mentioned in part (a) are given in the enclosed Statement *(See* below)

(f) The amounts from other formulators would be recovered as per due process of law.

Statement

(Rs. in lakhs)

Gentamycin '	Tentative amount assessed
(3) M/s. Lyka Labs. Ltd	17.47
Metronidazole	
(2) M/s. Smith Stanistreet Pharmaceuticals Ltd.	7.02
(3) M/s. K.S.D.P.L.	5.50

Unintended Benefit on Pyrimon

2428. SHRI SANTOSH KUMAR SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) what was the price-of Pyrimon fixed under DPCO, 1987 and when it was fixed;

(b) what was the price fixed under DPCO, 1979 and what was the price at which this product was sold;

(c) what is the present price .at which this durg is being sold;

(d) whether it is a fact that this product has been selling at a higher price than that approved; and

(e) what steps have been taken to stop overcharging and recover the unintended benefit ?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) to (e) The required information to the extent